DUBLIN, April 28, 2014 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) announced today the appointment of Hemanth J. Varghese, Ph.D., CFA, as executive vice president of corporate development and strategy, effective immediately.
Dr. Varghese brings to Endo a successful track record in corporate development and general management in specialty pharmaceuticals, most recently serving as the senior vice president and general manager vision care for Bausch & Lomb, a division of Valeant Pharmaceuticals. During his tenure with Valeant, Dr. Varghese held various senior leadership roles including senior vice president of corporate development and general manager of Valeant's Neurology & Other business unit. Over his career he has completed more than 40 corporate transactions, leading corporate development and integration initiatives including public/private acquisitions, investments, partnerships, licenses and divestitures. In his new global role with Endo, Dr. Varghese will report to Rajiv De Silva, Endo's president and chief executive officer. Dr. Robert Cobuzzi, who previously served as senior vice president, corporate development, will transition to the role of senior vice president, U.S. branded pharmaceuticals R&D strategy and operations.
"We are excited to announce the addition of Hemanth to the Endo executive team. His accomplishments and experience in corporate development and integrations will allow us to accelerate the execution of our strategy as we continue to expand our business through value creating acquisitions and partnerships," said Rajiv De Silva. "Hemanth's track record of success will play a significant role as we execute against our strategy to become a leading specialty healthcare company."
"I am thrilled to become part of Endo's management team during this important time for the Company as they embrace the opportunity to strategically grow through acquisitions on a global scale," stated Dr. Varghese. "My goal is to rapidly generate new revenue streams both in the domestic and international markets and I look forward to contributing to the next stage of growth."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts